Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6E1N4)

• Drug Name: Quinoline and quinazoline derivative 10 Drug Info
• Synonyms: PMID28621580-Compound-WO2014127335c34
• Cross-matching ID: TTD Drug ID: DM6E1N4

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[2]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[3]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[4]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[5]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[6]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[7]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[8]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[9]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[10]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[1]

References

• [1] VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [5] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [6] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [7] Clinical pipeline report, company report or official report of Genentech (2009).
• [8] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [9] Bispecific antibodies and their applications
• [10] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)